Webinar | August 2, 2024

Organ-Chip Quantitative Analysis: How To Confidently Predict Toxicity Of Preclinical Drug Candidates With The Emulate Liver-Chip

Source: Emulate

Drug-induced liver injury (DILI) is a potentially fatal condition that significantly impacts the pharmaceutical industry, leading to drug withdrawals and about 13% of clinical trial failures. The high incidence of DILI highlights the limitations of preclinical toxicology models in replicating the complexity of human liver physiology and drug responses.

Recent studies indicate that incorporating the Emulate Liver-Chip into preclinical workflows could decrease DILI-related clinical trial failures. We introduce a quantitative framework for integrating Liver-Chip data into pharmaceutical decision-making. This new Liver-Chip DILI score allows researchers to categorize compounds into standard DILI risk categories using human Liver-Chip and animal in vivo data.

Specifically, this webinar covers:

  • Characterization results of the Emulate Liver-Chip for DILI prediction
  • Integration points for the Liver-Chip in the preclinical workflow
  • Using the Liver-Chip’s quantitative readouts to classify therapeutics into DILI risk categories
  • Methodology for combining Liver-Chip data with animal in vivo data for a comprehensive DILI risk assessment

The presentation concluded with an informative Q&A session.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online